Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.63 |
| ▸ | HTR7 | P34969 | 4/20 | 0.63 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13096995 | 0.84 | HTR1A (0.63) | HTR1AHTR7DRD2HTR2AKCNH2 | |
| SCHEMBL16088497 | 0.84 | HTR1A (0.63) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL1406371 | 0.82 | HTR1A (0.43) | HTR1AHTR7DRD2HTR2A | |
| SCHEMBL1322961 | 0.80 | HTR1D (0.55) | HTR1ADRD2HTR2A | |
| SCHEMBL29515592 | 0.79 | HTR1A (0.80) | HTR1AHTR7DRD2HTR2AHTR6 | |
| SCHEMBL5763172 | 0.78 | HTR1A (0.60) | HTR1AHTR7DRD2HTR2AKCNH2 | |
| SCHEMBL1323836 | 0.77 | HTR1A (0.47) | HTR1ADRD2HTR2AKCNH2HTR6 | |
| SCHEMBL1322969 | 0.77 | HTR1A (0.57) | HTR1A | |
| SCHEMBL6748040 | 0.77 | HTR1A (0.52) | HTR1AHTR7DRD2HTR2AKCNH2 | |
| SCHEMBL6747707 | 0.77 | HTR1A (0.52) | HTR1AHTR7DRD2HTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058277-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2011-11-15 | — | — | US | claimed |
| EP-1497279-B1 | SUBSTITUTED INDOLES AND THEIR USE AS 5HT-REUPTAKE INHIBITORS AND AS 5HT LIGANDS | MERCK PATENT GMBH (DE) | 2011-03-09 | — | — | EP | claimed |
| US-20090291963-A1 | SUBSTITUTED INDOLES | SCHADT OLIVER | 2009-11-26 | — | — | US | claimed |
| US-7572796-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2009-08-11 | — | — | US | claimed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | claimed |
| US-20050153980-A1 | Substituted indoles | MERCK PATENT GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| US-20170173009-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. | 2017-06-22 | — | — | US | disclosed |
| US-9656955-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9586945-B2 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9586942-B2 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-07 | — | — | US | disclosed |
| US-9550754-B2 | 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-01-24 | — | — | US | disclosed |
| US-9365512-B2 | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-06-14 | — | — | US | disclosed |
| US-7572796-B2 | Substituted indoles | MERCK PATENT GMBH (DE) | 2009-08-11 | — | — | US | disclosed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | disclosed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | disclosed |
| US-20090054459-A1 | Substituted indoles | SCHADT OLIVER | 2009-02-26 | — | — | US | disclosed |
| US-20050153980-A1 | Substituted indoles | MERCK PATENT GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| EP-1497279-A2 | SUBSTITUTED INDOLES AND THEIR USE AS 5HT-REUPTAKE INHIBITORS AND AS 5HT LIGANDS | MERCK PATENT GmbH (DE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087086-A2 | SUBSTITUTED INDOLES | MERCK PATENT GMBH (DE) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172993-A1 | Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | AADAT, BCAT1, GFPT1 | HTR1A 358/4885HTR7 441/4885DRD2 847/4885 |
| US-20090054459-A1 | Substituted indoles | TPH2, TPH1, HTR1A | HTR1A 3/4885HTR7 15/4885DRD2 25/4885 |
| US-20090291963-A1 | SUBSTITUTED INDOLES | TPH2, TPH1, HTR1A | HTR1A 3/4885HTR7 16/4885DRD2 24/4885 |
| US-20050153980-A1 | Substituted indoles | TPH2, TPH1, HTR1A | HTR1A 3/4885HTR7 16/4885DRD2 24/4885 |
| US-20170173009-A1 | Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy | SLC7A1, BCAT1, AADAT | HTR1A 274/4885HTR7 469/4885DRD2 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.